

ClaroNav

MicronMapper: Precision redefined for full-arch dentistry

MicronMapper marks a breakthrough in full-arch dentistry, delivering exceptional accuracy and efficiency through cutting-edge photogrammetry technology. Having achieved CE mark approval in September 2024, MicronMapper is now available for European clinics, providing reliable, precise results in complex full-arch implant cases.

Designed to overcome common challenges in restorative dentistry, MicronMapper captures implant positions within 20 microns. This precision is critical for achieving a passive fit, reducing risks like screw loosening and implant stress—factors essential for long-term patient outcomes. By minimising manual adjustments and eliminating the need for verification jigs, MicronMapper enables clinicians to deliver faster, more consistent results with fewer patient visits.

Key Benefits of MicronMapper

- **Unmatched precision:** Leveraging true photogrammetry, MicronMapper ensures optimal

passive fit for full-arch cases, allowing clinicians to streamline workflows and increase reliability.

- **Enhanced efficiency:** MicronMapper's data capture integrates into existing workflows, reducing chair time and boosting patient throughput by minimising rework.
- **Clear ROI:** By cutting down on costly rework and follow-up appointments, MicronMapper improves operational efficiency, offering clinics a strong return on investment while elevating patient satisfaction.

MicronMapper sets a new benchmark in dental technology, merging precision with operational ease. For clinics aiming to lead in digital dentistry, MicronMapper is an indispensable tool for achieving outstanding clinical results and enhancing the patient experience. For distribution or purchase inquiries, please contact.



ClaroNav Inc.
info@claronav.com
www.claronavdental.com

MICRONMAPPER

Geistlich Pharma

Geistlich receives MDR approval for entire product portfolio

The entire Geistlich product portfolio has been successfully certified according to MDR—well before the official transition period. The pioneer in medical regeneration thus confirms its claim to meet the highest quality and safety standards.

As one of the first companies in its field, the regeneration specialist Geistlich has successfully completed the approval process for its entire product portfolio in accordance with the new Medical Device Regulation (MDR) of the European Union (EU) 2017/745. Geistlich thus meets the highest European standards of quality, safety and performance for medical devices.

For MDR certification, clinical and preclinical evidence as well as safety and performance data were thoroughly reviewed. Since the project to achieve certification started in 2017, Geistlich has submitted more than 2,200 documents with almost 40,000 pages and had its quality management system audited according to MDR. The entire process required several years of collaboration between teams from different departments and shows how challenging it is to obtain MDR approval even for established products. “Without the solid scientific basis of our products and our high quality standards, MDR certification would not have been possible so quickly,” says Diego Gabathuler, CEO of Geistlich.

The early MDR certification of all Geistlich products, even before the official deadline in 2027, underlines the company's strong commitment to the highest quality and safety standards. The certification is both proof and an incentive to continue to provide safe and effective solutions for patients and healthcare professionals, and to continue to advance the field of medical regeneration.



Geistlich Pharma AG
+41 41 4925555
info@geistlich.com
www.geistlich-pharma.com

*The articles in this category are provided by the manufacturers or distributors and do not reflect the opinion of the editorial team.

Carl Martin

Zygoma—double hook—full arch retractor

Carl Martin GmbH, based in Solingen, Germany, has collaborated with Dr Armando Lopes of the MALO CLINIC in Lisbon, Portugal, to launch a newly redesigned series of retractors. The series was unveiled at this year's EAO Congress in Milan, Italy, where it received significant attention.

"The event was a tremendous success. Our international audience experienced firsthand the advantages of these innovative instruments at our booth, with Dr Lopes' live demonstration highlighting their benefits," said Junior CEO Philip Holzknacht.

Additional presentations for professionals interested in surgical and implantological advancements were held at the 53rd International Annual Congress of DGZI in Düsseldorf, the 40th Annual Meeting of the BDO in Berlin, and will also be presented at the 38th DGI Congress in Dresden from 28–30 November.

Carl Martin GmbH

info@carlmartin.de • www.carlmartin.de



Florian Giesen, Technical Development and Sales at Carl Martin, Dr Armando Lopes, developer of the retractors, and Philip Holzknacht, Junior Managing Director at Carl Martin (from left) during the EAO Congress in Milan.

epitome

Novel dental cleaning device removes biofilm by up to 99 per cent

The "e1" by epitome represents a significant advancement in dental hygiene technology, diverging entirely from conventional toothbrushes in both design and function. As the world's first autonomous dental cleaning device, e1 was meticulously developed by a high-tech company in Vienna between 2018 and 2024. This innovative device employs sophisticated artificial intelligence to conduct a comprehensive analysis of the teeth, subsequently executing a thorough cleaning in under 60 seconds. Utilising 50 advanced sensors and 14 nano-cameras, e1 accurately detects biofilm accumulation and effectively targets its removal in a sequential process. The efficacy of this "intelligent cleaning" protocol has been substantiated through rigorous laboratory testing, demonstrating a remarkable cleaning efficiency and reach of up to 99 per cent¹ within a mere 30 seconds² for both the maxillary and mandibular arches.

Upon completion of the cleaning cycle, users receive an indepth analysis detailing critical health metrics, including body temperature, heart rate, blood pressure, cortisol levels, and oxygen



saturation, thus promoting an integrated approach to oral and overall health.

The research and development of e1 involved collaboration with esteemed experts in the field of biofilm research, including Prof. Georgios Belibasakis, Dr Reinhard Gruber (Professor of Oral Biology at the University Dental Clinic of Vienna), and Prof. Barbara Cvikl (Sigmund Freud Private University Vienna).

e1 is available for order through the company's online shop, and interested individuals are cordially invited to experience this groundbreaking product at the pop-up store located at Kohlmarkt 10 in Vienna, Austria.

¹ Referring to the detected tooth surface.

² The cleaning time depends on the jaw structure, tooth alignment, and the amount of biofilm/plaque.

epitome GmbH • +49 30 22405959

support@epitome.inc • www.epitome.inc



epitome

© epitome